Ladenburg Thalmann Financial Services’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-22,193
| Closed | -$82K | – | 5327 |
|
|
2017
Q4 | $82K | Hold |
22,193
| – | – | ﹤0.01% | 2868 |
|
|
2017
Q3 | $91K | Hold |
22,193
| – | – | ﹤0.01% | 2675 |
|
|
2017
Q2 | $82K | Hold |
22,193
| – | – | ﹤0.01% | 2643 |
|
|
2017
Q1 | $92K | Buy |
22,193
+8,747
| +65% | +$36.8K | ﹤0.01% | 2462 |
|
|
2016
Q4 | $58K | Sell |
13,446
-2
| -0% | -$13 | ﹤0.01% | 2740 |
|
|
2016
Q3 | $133K | Hold |
13,448
| – | – | ﹤0.01% | 2051 |
|
|
2016
Q2 | $76K | Buy |
13,448
+2,092
| +18% | +$14.2K | ﹤0.01% | 2361 |
|
|
2016
Q1 | $87K | Sell |
11,356
-33
| -0.3% | -$254 | ﹤0.01% | 2166 |
|
|
2015
Q4 | $151K | Hold |
11,389
| – | – | ﹤0.01% | 1775 |
|
|
2015
Q3 | $187K | Buy |
11,389
+2,079
| +22% | +$42.6K | ﹤0.01% | 1531 |
|
|
2015
Q2 | $209K | Sell |
9,310
-43
| -0.5% | -$680 | ﹤0.01% | 1579 |
|
|
2015
Q1 | $92K | Hold |
9,353
| – | – | ﹤0.01% | 2135 |
|
|
2014
Q4 | $107K | Buy |
9,353
+1,432
| +18% | +$15.5K | ﹤0.01% | 1847 |
|
|
2014
Q3 | $91K | Hold |
7,921
| – | – | ﹤0.01% | 1658 |
|
|
2014
Q2 | $154K | Buy |
7,921
+1,022
| +15% | +$18K | ﹤0.01% | 1344 |
|
|
2014
Q1 | $124K | Buy |
6,899
+2,419
| +54% | +$39.7K | ﹤0.01% | 1373 |
|
|
2013
Q4 | $47K | Hold |
4,480
| – | – | ﹤0.01% | 1962 |
|
|
2013
Q3 | $55K | Hold |
4,480
| – | – | ﹤0.01% | 1764 |
|
|
2013
Q2 | $42K | Buy |
+4,480
| New | +$57.5K | ﹤0.01% | 1851 |
|
Ladenburg Thalmann Financial Services's CASC Position: Q1 2018 in Review
Ladenburg Thalmann Financial Services sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 22,193 shares — an estimated $82K sold.
Ladenburg Thalmann Financial Services first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $209K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Ladenburg Thalmann Financial Services reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Ladenburg Thalmann Financial Services sold 22,193 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $82K.
- Ladenburg Thalmann Financial Services first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Ladenburg Thalmann Financial Services's Cascadian Therapeutics, Inc. position peaked at $209K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2018, filed 15 May 2018.